(1)

I del 3 ska tabell 3 ändras på följande sätt: a) Följande poster ska införas: Index nr Kemiskt namn EG-nr CAS-nr Klassificering Märkning Särskilda koncentrationsgränser, M-faktorer och uppskattad akut toxicitet (ATE) Anm.: Faroklass och farokategorikod(er) Faroangivelsekod(er) Faropiktogram, signalordskod(er) Faroangivelsekod(er) Kompl. faroangivelsekod(er) ”014-052-00–7 silanamin, 1,1,1-trimetyl-N-(trimetylsilyl)-, hydrolysprodukter med kiseldioxid; pyrogen, syntetisk amorf ytbehandlad kiseldioxid, nano 272-697-1 68909-20-6 STOT RE 2 H373 (lungor) (inhalation) GHS08 Wng H373 (lungor) (inhalation) EUH066” ”035-005-00–7 ammoniumbromid 235-183-8 12124-97-9 Repr. 1B Lact. STOT SE 3 STOT RE 1 Eye Irrit. 2 H360FD H362 H336 H372 (nervsystem) H319 GHS08 GHS07 Dgr H360FD H362 H336 H372 (nervsystem) H319” ”050-032-00–4 dibutyltennbis(2-etylhexanoat) 220-481-2 2781-10-4 Muta. 2 Repr. 1B STOT RE 1 H341 H360FD H372 (immunsystem) GHS08 Dgr H341 H360FD H372 (immunsystem)” ”050-033-00-X dibutyltenndi(acetat) 213-928-8 1067-33-0 Muta 2 Repr. 1B STOT RE 1 H341 H360FD H372 (immunsystem) GHS08 Dgr H341 H360FD H372 (immunsystem)” ”052-001-00–0 tellur 236-813-4 13494-80-9 Repr. 1B Lact. H360Df H362 GHS08 Dgr H360Df H362” ”052-002-00–6 tellurdioxid 231-193-1 7446-07-03 Repr. 1B Lact. H360Df H362 GHS08 Dgr H360Df H362” ”056-005-00–3 bariumdibortetraoxid 237-222-4 13701-59-2 Repr. 1B Acute Tox. 4 Acute Tox. 3 H360FD H332 H301 GHS08 GHS06 Dgr H360FD H332 H301 inhalation: ATE = 1,5 mg/l (damm eller dimma) oral: ATE = 100 mg/kg bw” ”601-097-00–8 propylbensen 203-132-9 103-65-1 Flam. Liq. 3 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 H226 H304 H335 H411 GHS02 GHS08 GHS07 GHS09 Dgr H226 H304 H335 H411” ”603-243-00–6 2,2-dimetylpropan-1-ol, tribromderivat; 3-brom-2,2-bis(brommetyl)propan-1-ol 253-057-0 36483-57-5; 1522-92-5 Carc. 1B Muta. 2 H350 H341 GHS08 Dgr H350 H341” ”604-096-00–0 piperonylbutoxid (ISO); 2-(2-butoxietoxi)etyl-6-propylpiperonyleter 200-076-7 51-03-6 STOT SE 3 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H335 H319 H400 H410 GHS07 GHS09 Wng H335 H319 H410 EUH066 M = 1 M = 1” ”604-097-00–6 2,4,6-tri-tert-butylfenol 211-989-5 732-26-3 Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1B H360D H302 H373 (lever) H317 GHS08 GHS07 Dgr H360D H302 H373 (lever) H317 oral: ATE = 500 mg/kg bw” ”604-098-00–1 4,4’-sulfonyldifenol; bisfenol S 201-250-5 80-09-1 Repr. 1B H360FD GHS08 Dgr H360FD” ”606-153-00–5 bensofenon 204-337-6 119-61-9 Carc. 1B H350 GHS08 Dgr H350” ”606-154-00–0 kinoklamin (ISO); 2-amino-3-klor-1,4-naftokinon 220-529-2 2797-51-5 Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H351 H361d H302 H373 (blodsystem, njurar) H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361d H302 H373 (blodsystem, njurar) H319 H317 H410 oral: ATE = 500 mg/kg bw M = 10 M = 10” ”607-756-00–6 exo-1,7,7-trimetylbicyklo[2.2.1]hept-2-ylakrylat; isobornylakrylat 227-561-6 5888-33-5 Skin Sens. 1A H317 GHS07 Wng H317” ”607-757-00–1 daminozid (ISO); 4-(2,2-dimetylhydrazino)-4-oxobutansyra; N-dimetylaminosuccinamidsyra 216-485-9 1596-84-5 Carc. 2 H351 GHS08 Wng H351” ”607-758-00–7 4,4’-oxidi(bensensulfonohydrazid) 201-286-1 80-51-3 Self-react. D Aquatic Acute 1 Aquatic Chronic 1 H242 H400 H410 GHS02 GHS09 Dgr H242 H410 M = 1 M = 1” ”607-759-00–2 toluen-4-sulfonhydrazid 216-407-3 1576-35-8 Self-react. D H242 GHS02 Dgr H242” ”607-760-00–8 2-[N-etyl-4-[(5-nitrotiazol-2-yl)azo]-m-toluidino]etylacetat; C.I. Disperse Blue 124 239-203-6 15141-18-1 Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0001 %” ”607-761-00–3 perfluorheptansyra; tridekafluorheptansyra 206-798-9 375-85-9 Repr. 1B STOT RE 1 H360D H372 (lever) GHS08 Dgr H360D H372 (lever)” ”607-762-00–9 metyl-N-(isopropoxikarbonyl)-L-valyl-(3RS)-3-(4-klorfenyl)-β-alaninat valifenalat - 283159-90-0 Carc. 2 Aquatic Chronic 2 H351 H411 GHS08 GHS09 Wng H351 H411” ”607-763-00–4 6-[C12-18-alkyl-(grenad, omättad)-2,5-dioxopyrrolidin-1-yl]hexansyra, natrium- och tris(2-hydroxietyl)ammoniumsalter - - Repr. 1B Eye Irrit. 2 H360FD H319 GHS08 GHS07 Dgr H360FD H319” ”607-764-00-X 6-[(C10–C13)-alkyl-(grenad, omättad)-2,5-dioxopyrrolidin-1-yl]hexansyra - 2156592-54-8 Repr. 1B Eye Irrit. 2 H360FD H319 GHS08 GHS07 Dgr H360FD H319” ”607-765-00–5 6-[C12-18-alkyl-(grenad, omättad)-2,5-dioxopyrrolidin-1-yl]hexansyra - - Repr. 1B H360FD GHS08 Dgr H360FD” ”613-341-00–0 klofentezin (ISO); 3,6-bis(o-klorfenyl)-1,2,4,5-tetrazin 277-728-2 74115-24-5 Aquatic Chronic 1 H410 GHS09 Wng H410 M = 1” ”613-342-00–6 teofyllin; 1,3-dimetyl-3,7-dihydro-1H-purin-2,6-dion 200-385-7 58-55-9 Repr. 1B H360D GHS08 Dgr H360D” ”613-343-00–1 pyridalyl (ISO); 2,6-diklor-4-(3,3-diklorallyloxi)fenyl-3-[5-(trifluormetyl)-2-pyridyloxi]propyleter - 179101-81-6 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 M = 1 000 M = 100” ”613-344-00–7 2-pyridin-tiol-1-oxid, natriumsalt; pyritionnatrium; natriumpyrition 223-296-5; 240-062-8 3811-73-2; 15922-78-8 Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 2 H331 H311 H302 H372 (nervsystem) H315 H319 H317 H400 H411 GHS06 GHS08 GHS09 Dgr H331 H311 H302 H372 (nervsystem) H315 H319 H317 H410 EUH070 inhalation: ATE = 0,5 mg/l (damm eller dimma) dermal: ATE = 790 mg/kg bw oral: ATE = 500 mg/kg bw M = 100” ”613-345-00–2 1,3,5-triazin-2,4,6-triamin; melamin 203-615-4 108-78-1 Carc. 2 STOT RE 2 H351 H373 (urinvägar) GHS08 Wng H351 H373 (urinvägar)” ”615-046-00–2 1,3-bis(1-isocyanat-1-metyletyl)bensen; [m-TMXDI] 220-474-4 2778-42-9 Resp. Sens. 1 Skin Sens. 1A H334 H317 GHS08 Dgr H334 H317” ”615-047-00–8 1,3-bis(isocyanatmetyl)bensen; [m-XDI] 222-852-4 3634-83-1 Resp. Sens. 1 Skin Sens. 1A H334 H317 GHS08 Dgr H334 H317 Skin Sens. 1A; H317: C ≥ 0001 %” ”615-048-00–3 2,4,6-triisopropyl-m-fenylendiisocyanat 218-485-4 2162-73-4 Resp. Sens. 1 Skin Sens. 1 H334 H317 GHS08 Dgr H334 H317” ”615-049-00–9 1,5-naftylendiisocyanat [innehållande < 0,1 % (w/w) partiklar med en aerodynamisk diameter under 50 μm] 221-641-4 3173-72-6 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3 H335 H315 H319 H334 H317 H412 GHS07 GHS08 Dgr H335 H315 H319 H334 H317 H412” ”615-050-00–4 1,5-naftylendiisocyanat [innehållande ≥ 0,1 % (w/w) partiklar med en aerodynamisk diameter under 50 μm] 221-641-4 3173-72-6 Acute Tox. 2 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3 H330 H335 H315 H319 H334 H317 H412 GHS06 GHS08 Dgr H330 H335 H315 H319 H334 H317 H412 inhalation: ATE = 0,27 mg/l (damm eller dimma)” ”616-237-00–3 fluopikolid (ISO); 2,6-diklor-N-[3-klor-5-(trifluormetyl)-2-pyridylmetyl]bensamid - 239110-15-7 Repr. 2 H361d GHS08 Wng H361d” ”616-238-00–9 N-(2-nitrofenyl)fosfortriamid 477-690-9 874819-71-3 Repr. 1B STOT RE 2 H360Fd H373 (njurar) GHS08 Dgr H360Fd H373 (njurar)” ”616-239-00–4 N-(5-klor-2-isopropylbensyl)-N-cyklopropyl-3-(difluormetyl)-5-fluor-1-metyl-1H-pyrazol-4-karboxamid; isoflucypram - 1255734-28-1 Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H361f H332 H317 H400 H410 GHS08 GHS07 GHS09 Wng H361f H332 H317 H410 inhalation: ATE = 2,2 mg/l (damm eller dimma) M = 10 M = 1’ ”616-240-00-X Reaktionsblandning av 3-(difluormetyl)-1-metyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-metanonaftalen-5-yl]pyrazol-4-karboxamid och 3-(difluormetyl)-1-metyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-metanonaftalen-5-yl]pyrazol-4-karboxamid ≥ 78 % syn-isomerer ≤ 15 % anti-isomerer relativt innehåll]; isopyrazam - 881685-58-1 Carc. 2 Repr. 1B Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H351 H360D H317 H400 H410 GHS08 GHS07 GHS09 Dgr H351 H360D H317 H410 Repr. 1B; H360D: C ≥ 3 % M = 10 M = 10” ”650-058-00–1 margosaextrakt, [från kärnor av Azadirachta indica extraherat med vatten och vidare bearbetat med organiska lösningsmedel] 283-644-7 84696-25-3 Repr. 2 Skin Sens. 1 Aquatic Chronic 1 H361d H317 H410 GHS08 GHS07 GHS09 Wng H361d H317 H410 M = 10” b) Posterna för indexnummer 014-001-00–9; 023-001-00–8; 601-024-00-X; 603-014-00–0; 603-107-00–6; 604-030-00–0; 607-111-00–9; 607-230-00–6; 607-253-00–1; 607-254-00–7; 607-734-00–6; 607-735-00–1; 607-736-00–7; 608-032-00–2; 609-042-00-X; 613-012-00–1; 616-164-00–7 och 616-113-00–9 ska ersättas med följande: Index nr Kemiskt namn EG-nr CAS-nr Klassificering Märkning Särskilda koncentrationsgränser, M-faktorer och uppskattad akut toxicitet (ATE) Anm.: Faroklass och farokategorikod(er) Faroangivelsekod(er) Faropiktogram, signalordskod(er) Faroangivelsekod(er) Kompl. faroangivelsekod(er) ”014-001-00–9 triklorsilan 233-042-5 10025-78-2 Flam. Liq. 1 Water-react. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 H224 H260 H331 H302 H314 H318 GHS02 GHS06 GHS05 Dgr H224 H260 H331 H302 H314 EUH014 EUH029 EUH071 inhalation: ATE = 7,6 mg/l (ånga) oral: ATE = 1 000 mg/kg bw” ”023-001-00–8 divanadinpentoxid; vanadinpentoxid 215-239-8 1314-62-1 Muta. 2 Carc. 1B Repr. 2 Lact. Acute Tox. 3 Acute Tox. 2 STOT SE 3 STOT RE 1 Aquatic Chronic 2 H341 H350 H361fd H362 H301 H330 H335 H372 (luftvägar) (inhalation) H411 GHS06 GHS08 GHS09 Dgr H341 H350 H361fd H362 H301 H330 H335 H372 (luftvägar) (inhalation) H411 inhalation: ATE = 0,05 mg/l (damm eller dimma) oral: ATE = 220 mg/kg bw” ”601-024-00-X Kumen 202-704-5 98-82-8 Flam. Liq. 3 Carc. 1B Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 H226 H350 H304 H335 H411 GHS02 GHS08 GHS07 GHS09 Dgr H226 H350 H304 H335 H411” ”603-014-00–0 2-butoxietanol; etylenglykolmonobutyleter 203-905-0 111-76-2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 H331 H302 H315 H319 GHS06 Dgr H331 H302 H315 H319 inhalation: ATE = 3 mg/l (ånga) oral: ATE = 1 200 mg/kg bw” ”603-107-00–6 2-(2-metoxietoxi)etanol; dietylenglykolmonometyleter 203-906-6 111-77-3 Repr. 1B H360D GHS08 Dgr H360D Repr. 1B; H360D: C ≥ 3 %” ”604-030-00–0 4,4’-isopropylidendifenol; bisfenol A 201-245-8 80-05-7 Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360F H335 H318 H317 H400 H410 GHS08 GHS07 GHS05 GHS09 Dgr H360F H335 H318 H317 H410 M = 1 M = 10” ”607-111-00–9 2-etyl-2-[[(1-oxoallyl)oxi]metyl]-1,3-propandiyldiakrylat; 2,2-bis(akryloyloximetyl)butylakrylat; trimetylolpropantriakrylat 239-701-3 15625-89-5 Carc. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H315 H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H315 H319 H317 H410 M = 1 M = 1 D” ”607-230-00–6 2-etylhexansyra och dess salter utom sådana som är upptagna på annat ställe i denna bilaga - - Repr. 1B H360D GHS08 Dgr H360D” ”607-253-00–1 cyflutrin (ISO); α-cyano-4-fluor-3-fenoxibensyl-3-(2,2-diklorvinyl)-2,2-dimetylcyklopropankarboxylat 269-855-7 68359-37-5 Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H362 H330 H300 H370 (nervsystem) H400 H410 GHS06 GHS08 GHS09 Dgr H362 H330 H300 H370 (nervsystem) H410 inhalation: ATE = 0,14 mg/l (damm eller dimma) oral: ATE = 14 mg/kg bw M = 1 000 000 M = 1 000 000 ” ”607-254-00–7 beta-cyflutrin (ISO); Reaktionsblandning av rel-(R)-cyano(4-fluor-3-fenoxifenyl)metyl(1S,3S)-3-(2,2-dikloretenyl)-2,2-dimetylcyklopropan-1-karboxylat och rel-(R)-cyano(4-fluor-3-fenoxifenyl)metyl(1S,3R)-3-(2,2-dikloretenyl)-2,2-dimetylcyklopropan-1-karboxylat - 1820573-27-0 Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H362 H330 H300 H370 (nervsystem) H400 H410 GHS06 GHS08 GHS09 Dgr H362 H330 H300 H370 (nervsystem) H410 inhalation: ATE = 0,081 mg/l (damm eller dimma) oral: ATE = 11 mg/kg bw M = 1 000 000 M = 1 000 000 ” ”607-734-00–6 pentakalium-2,2’,2",2"’,2""-(etan-1,2-diylnitril)pentaacetat 404-290-3 7216-95-7 Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2 H360D H332 H373 (inhalation) H319 GHS08 GHS07 Dgr H360D H332 H373 (inhalation) H319 Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/l (damm eller dimma)” ”607-735-00–1 N-karboximetyliminobis(etylennitril)tetraättiksyra 200-652-8 67-43-6 Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2 H360D H332 H373 (inhalation) H319 GHS08 GHS07 Dgr H360D H332 H373 (inhalation) H319 Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/l (damm eller dimma)” ”607-736-00–7 pentanatrium(karboxylatmetyl)iminobis(etylennitril)tetraacetat 205-391-3 140-01-2 Repr. 1B Acute Tox. 4 STOT RE 2 H360D H332 H373 (inhalation) GHS08 GHS07 Dgr H360D H332 H373 (inhalation) Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/l (damm eller dimma)” ”608-032-00–2 acetamiprid (ISO); (1E)-N-[(6-klorpyridin-3-yl)metyl]-N’-cyano-N-metyletanimidamid; (E)-N1-[(6-klor-3-pyridyl)metyl]-N2-cyano-N1-metylacetamidin - 135410-20-7 160430-64-8 Repr. 2 Acute Tox. 3 Aquatic Chronic 1 Aquatic Acute 1 H361d H301 H410 H400 GHS08 GHS06 GHS09 Dgr H361d H301 H410 oral: ATE = 140 mg/kg bw M = 10 M = 10” ”609-042-00-X pendimetalin (ISO); N-(1-etylpropyl)-2,6-dinitro-3,4-xyliden 254-938-2 40487-42-1 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H400 H410 GHS08 GSH09 Wng H361d H410 M = 100 M = 10” ”613-012-00–1 bentazon (ISO); 3-isopropyl-2,1,3-bensotiadiazin-4-on-2,2-dioxid 246-585-8 25057-89-0 Repr. 2 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1 H361d H302 H319 H317 GHS08 GHS07 Wng H361d H302 H319 H317 oral: ATE = 1 600 mg/kg bw” ”616-164-00–7 dimoxistrobin (ISO); (2E)-2-{2-[(2,5-dimetylfenoxi)metyl]fenyl}-2-(metoxiimino)-N-metylacetamid; (E)-2-(metoxiimino)-N-metyl-2-[α-(2,5-xylyloxi)-o-tolyl]acetamid 149961-52-4 Carc. 2 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H351 H361d H332 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361d H332 H410 inhalation: ATE = 1,3 mg/l (damm eller dimma) M = 100 M = 100” c) Posten för indexnummer 615-007-00-X ska utgå.